GWave technology revolutionizes accuracy of noninvasive glucose monitoring devices

      The noninvasive GWave device technology is based on the electrical reaction of biological tissue in the dermis to the broadcasted RF wave and the dielectric change in the tissue in correlation with the change of blood glucose levels. The technology’s potential to improve the accuracy of noninvasive glucose monitoring devices showed green signal in a recent research conducted in a significant number of individuals (type 2 diabetes, n = 6; type 1 diabetes, n = 28; nondiabetic pregnant subjects, n = 10; and nondiabetic, n = 31). The observations from the study revealed that the level of accuracy could be reproduced in a larger cohort, using a smaller third-generation manufacturable device (Gen III GWave) containing a standardized sensor chip. The evaluation assessed concordance with capillary blood glucose, reproducibility between two Gen III devices, and accuracy during insulin-induced hypoglycemia. The accuracy of the device that used GWave technology fell under the agreeable zones of Clarks Error Grid with a mean absolute relative difference of 6.7% from reference blood glucose. Comparison between two independent Gen III GWave devices demonstrated reproducibility between the sensors with 100% of values within Zone A of Clarks Error Grid. In the hypoglycemia assessment, measurements from the Gen III sensor tightly followed the capillary glucose measurements down to 42 mg/dL, whereas the CGM measurements from two different CGM only converged with the GWave and capillary glucose readings after 90 min of decreasing glucose levels. The study results are remarkable as the first of its kind as a noninvasive technology.